Haleon Stock Shows Positive Signs for Growth
Recent insights from industry specialists have highlighted a promising future for Haleon PLC (HLN:LN) (NYSE: HLN), which has sparked increased interest in its stock. Notably, Morgan Stanley has revised its price target for Haleon from GBP3.85 to GBP4.15, continuing to maintain an Overweight rating on the stock.
Analyst Predictions Boost Market Confidence
The latest analysis from Morgan Stanley indicates that Haleon is likely to outperform its European Staples competitors in the upcoming year. This optimism is largely attributed to strong market share trends and positive expectations for the second half of the year, which seem more favorable compared to earlier periods.
Forecasts for Organic Growth
The analysts at Morgan Stanley predict a significant uptick in Haleon’s organic growth, estimating it will reach +6.5% in the latter half of the year—up from +3.5% recorded earlier. This rise is expected to be driven by easier comparisons from the past, further enhancing Haleon’s performance in its sector.
Valuation Insights from Morgan Stanley
Despite the favorable indicators, Morgan Stanley recently removed Haleon from its Top Pick list, citing a notable re-rating of over 15% year-to-date for the stock. Currently, Haleon is trading at about 20.5 times its projected price-to-earnings ratio for 2025, which is approximately 20% above its peers in the European Staples sector.
Strong Growth Visibility Continues
Even with these adjustments, the Overweight rating remains intact, thanks to solid visibility regarding Haleon's growth in consumer categories that have proven to be resilient. The outlook suggests consistent high-single-digit growth in earnings per share over the next few years, positioning Haleon positively against its competitors.
Performance Amid Market Challenges
Highlighting Haleon’s strong performance, the analyst noted that the company is likely to continue outperforming its peers within the Home and Personal Care (HPC) and Food sectors, especially during a period of consumer softening in key markets, including the United States and China. The latest projections from Morgan Stanley reflect this optimistic trend.
Recent Financial Activity
In related news, Haleon has initiated a dual-tranche bond offering under its Euro Medium Term Note (EMTN) program, comprising €750 million in fixed-rate notes due in 2028 and £300 million maturing in 2033. The proceeds will primarily support general corporate needs, including the partial repayment of a $1.75 billion bond that matures in March 2025.
Further Insights from Analysts
BofA Securities has reiterated a Buy rating for Haleon, increasing its price target from £4.00 to £4.40. Analysts predict the company may enjoy a compound annual growth rate of 5.3% from 2023 to 2026, with projected earnings per share growth around 7.6%. On the other hand, Goldman Sachs has adjusted its rating from "Buy" to "Neutral," while Berenberg has initiated coverage with a positive “Buy” recommendation.
Innovative Product Developments
Additionally, Haleon has made significant strides in its product offerings with the launch of Eroxon®, recognized as the first FDA-cleared over-the-counter gel for treating erectile dysfunction in the United States. This new product is expected to hit major retail outlets by October 2024.
Strategic Corporate Developments
Haleon’s growth narrative is also marked by key organizational changes, including the recent appointments of Alan Stewart and Nancy Avila to its board. Furthermore, the company has announced that its total voting shares amount to 9,123,638,944. These developments signify an exciting chapter in Haleon's ongoing journey.
Frequently Asked Questions
What is the current stock target for Haleon PLC?
The price target for Haleon PLC has been raised to GBP4.15 by Morgan Stanley.
How is Haleon expected to perform against peers?
Haleon is predicted to outperform its peers in the European Staples sector, especially in the second half of the year.
What is the expected organic growth for Haleon this year?
Haleon is anticipated to achieve an organic growth rate of +6.5% in the latter half of the year.
What are the recent bond offerings by Haleon?
Haleon has initiated a dual-tranche bond offering totaling €750 million and £300 million as part of its EMTN program.
When is Eroxon® expected to be available?
Eroxon®, the new treatment for erectile dysfunction, is expected to be available in major retailers by October 2024.
